[ad_1]
The temporary suspension of the investigation, located in Phase 3, of the youth vaccine coronavirus, of AstraZeneca and the University of Oxfordsaid a company spokesperson after a suspected adverse reaction was reported in a patient who volunteered for the program in the UK.
An AstraZeneca spokesperson said that “A formal company review process has caused a pause in vaccination to allow for a review of safety data.”
No further details were given, although it was clarified that the life of the patient who had the reaction to vaccine.
An AstraZeneca spokesperson described the cessation of the investigation as “Routine steps should be taken whenever there is potentially unexplained illness in one of the research trials, ensuring that we maintain the integrity of the trials.”. The spokesperson also said that the company “He is working to expedite the review of the individual event to minimize any potential impact on the testing program.”
Researchers now look for similar cases of side effects by combining databases controlled by the so-called Security and Data Monitoring Council.
AstraZeneca began testing Phase 3 in the United States only in late August. The US trial is currently being conducted at 62 sites across the country, according to Clinicaltrials.gov, although some have yet to begin registering participants. Phase 2/3 trials have already started in the UK, Brazil and South Africa.
It was also unclear in which clinical trial the side effect occurred.
News Today
Fire in a forest area in the Faraklata area of Kefalonia
Wall Street: significant losses at Tuesday’s close
Nations League Overview – All Results and Scores
